{"protocolSection": {"identificationModule": {"nctId": "NCT06356311", "orgStudyIdInfo": {"id": "2870-015"}, "secondaryIdInfos": [{"id": "2023-505423-31", "type": "REGISTRY", "domain": "EU CT"}, {"id": "U1111-1291-7109", "type": "REGISTRY", "domain": "UTN"}, {"id": "MK-2870-015", "type": "OTHER", "domain": "MSD Id"}, {"id": "jRCT2031240133", "type": "REGISTRY", "domain": "Japan Registry of Clinical Trials (jRCT)"}], "organization": {"fullName": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}, "briefTitle": "A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)", "officialTitle": "A Phase 3, Multicenter, Open-label, Randomized Study to Compare the Efficacy and Safety of MK-2870 Versus Treatment of Physician's Choice in 3L+ Advanced/Metastatic Gastroesophageal Adenocarcinoma (Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, and Esophageal Adenocarcinoma)", "acronym": "TroFuse-015"}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "This study will compare how safe and effective sacituzumab tirumotecan is versus the treatment of physician's choice (TPC) in participants with advanced/metastatic gastroesophageal adenocarcinoma. The primary hypothesis of this study is sacituzumab tirumotecan is superior to TPC with respect to Overall Survival (OS)."}, "conditionsModule": {"conditions": ["Gastroesophageal Cancer"], "keywords": ["Gastroesophageal cancer", "Gastroesophageal adenocarcinoma", "Gastric adenocarcinoma", "Esophageal adenocarcinoma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "SINGLE", "whoMasked": ["OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 450, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "Sacituzumab tirumotecan", "type": "EXPERIMENTAL", "description": "Participants will receive sacituzumab tirumotecan at a dose of 4mg/kg by intravenous (IV) infusion on days 1, 15, and 29 of every 42-day cycle.", "interventionNames": ["Biological: Sacituzumab tirumotecan", "Drug: Rescue medication", "Drug: Supportive care measures"]}, {"label": "Treatment of Physician's Choice (TPC)", "type": "ACTIVE_COMPARATOR", "description": "TPC include either trifluridine-tipiracil (35 mg/m\\^2 orally (PO) twice a day (BID) on days 1 to 5 and 8 to 12 of every 28-day cycle), irinotecan (150 mg/m\\^2 IV on days 1 and 15 of every 28-day cycle), paclitaxel (80 mg/m\\^2 IV on days 1, 8, and 15 of every 28-day cycle), or docetaxel (75 mg/m\\^2 IV on day 1 of every 21-day cycle).", "interventionNames": ["Drug: Trifluridine-Tipiracil", "Drug: Irinotecan", "Drug: Paclitaxel", "Drug: Docetaxel", "Drug: Supportive care measures"]}], "interventions": [{"type": "BIOLOGICAL", "name": "Sacituzumab tirumotecan", "description": "Participants will receive sacituzumab tirumotecan as 4mg/kg IV infusion on days 1, 15, and 29 of every 42-day cycle.", "armGroupLabels": ["Sacituzumab tirumotecan"], "otherNames": ["SKB264. MK-2870"]}, {"type": "DRUG", "name": "Trifluridine-Tipiracil", "description": "Trifluridine-tipiracil will be administered at 35 mg/m\\^2 as tablet orally twice a day on days 1-5 and 8-12 of every 28-day cycle.", "armGroupLabels": ["Treatment of Physician's Choice (TPC)"]}, {"type": "DRUG", "name": "Irinotecan", "description": "Irinotecan will be administered at a dose of 150 mg/m\\^2 by IV infusion on days 1 and 15 of every 28-day cycle.", "armGroupLabels": ["Treatment of Physician's Choice (TPC)"]}, {"type": "DRUG", "name": "Paclitaxel", "description": "Paclitaxel will be administered at a dose of 80 mg/m\\^2 by IV infusion on days 1, 8 and 15 of every 28-day cycle.", "armGroupLabels": ["Treatment of Physician's Choice (TPC)"]}, {"type": "DRUG", "name": "Docetaxel", "description": "Docetaxel will be administered at a dose of 75 mg/m\\^2 by IV infusion on day 1 of a 21-day cycle.", "armGroupLabels": ["Treatment of Physician's Choice (TPC)"]}, {"type": "DRUG", "name": "Rescue medication", "description": "Participants are allowed to take rescue medication for stomatitis or oral mucositis. At the discretion of the investigator, participants are provided with a prescription for rescue medications. Recommended rescue medications are antihistamine, histamine-2 (H2) receptor antagonist, acetaminophen or equivalent, dexamethasone or equivalent infusion or steroid mouthwash (dexamethasone or equivalent), antiemetic medications, oral nystatin suspension or antifungal medications, antidiarrheal agents, antiemetic agents, opiate and non-opiate analgesic agents, appetite stimulants, and granulocyte and erythroid growth factors.", "armGroupLabels": ["Sacituzumab tirumotecan"]}, {"type": "DRUG", "name": "Supportive care measures", "description": "Participants are allowed to take supportive care measures for the management of adverse events associated with study intervention at the discretion of the investigator. Supportive care measures may include but are not limited to antidiarrheal agents, antiemetic agents, opiate and non-opiate analgesic agents, appetite stimulants, and granulocyte and erythroid growth factors.", "armGroupLabels": ["Sacituzumab tirumotecan", "Treatment of Physician's Choice (TPC)"]}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Has a histologically-or cytologically-confirmed diagnosis of advanced, unresectable or metastatic gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, or esophageal adenocarcinoma\n* Has measurable disease per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) as assessed by the local site investigator/radiology. Lesions situated in a previously-irradiated area are considered measurable if progression has been shown in such lesions.\n* Has received, and progressed on, at least 2 prior chemotherapy and/or immunotherapy regimens for advanced, unresectable or metastatic gastroesophageal adenocarcinoma.\n* Participants are eligible regardless of human epidermal growth factor receptor-2 (HER2) status. Participants who are HER2+ must have previously received trastuzumab where available/appropriate\n* Has adequate organ function\n* Has provided tumor tissue sample for determination of trophoblast cell-surface antigen 2 (TROP2) status by the central laboratory before randomization for stratification\n* Participants who have AEs due to previous anticancer therapies must have recovered to Grade \u22641 or baseline (except for alopecia and vitiligo). Participants with endocrine related AEs who are adequately treated with hormone replacement therapy are eligible\n* Has measurable disease per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 as assessed by the local site investigator/radiology\n* Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 3 days before randomization\n* Has ability to swallow oral medication for those who may receive trifluridine-tipiracil\n* Human immunodeficiency virus (HIV) infected participants must have well-controlled HIV on antiretroviral therapy (ART)\n* Hepatitis B surface antigen (HBsAg) positive participants are eligible if they have received hepatitis B virus (HBV) antiviral therapy and have undetectable HBV viral load\n* Participants with a history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable\n\nExclusion Criteria:\n\n* Has a history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or corneal disease that prevents/delays corneal healing\n* Has Grade \u22652 peripheral neuropathy\n* Has active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis, or chronic diarrhea)\n* Has uncontrolled, significant cardiovascular disease or cerebrovascular disease, including New York Heart Association Class III or IV congestive heart failure, unstable angina, myocardial infarction, uncontrolled symptomatic arrhythmia, prolongation of corrected QT interval (QTcF) to \\>480 ms, and/or other serious cardiovascular and cerebrovascular diseases within 6 months before the first dose of study intervention\n* Has accumulation of pleural, ascitic, or pericardial fluid requiring drainage or diuretic drugs within 2 weeks before the first dose of study intervention\n* Has received prior treatment with a trophoblast antigen 2(TROP2) targeted antibody-drug conjugate (ADC), a topoisomerase 1 inhibitor based, and/or a topoisomerase 1 inhibitor-based chemotherapy.\n* Has received prior systemic anticancer therapy within 2 weeks before the first dose of study intervention\n* Has received prior radiotherapy within 2 weeks before the first dose of study intervention, has radiation-related toxicities, requiring corticosteroids, and/or has had radiation pneumonitis\n* Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention\n* Is currently receiving a strong and/or moderate inducer/inhibitor of cytochrome P450 3A4 (CYP3A4) that cannot be discontinued for the duration of treatment with study intervention. The required washout period before starting study intervention is 2 weeks\n* Has received an investigational agent or has used an investigational device within 4 weeks before the first dose of study intervention\n* Has a known additional malignancy that is progressing or has required active treatment within the past 3 years\n* Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis\n* Has an active infection requiring systemic therapy\n* HIV infected participants with a history of Kaposi's sarcoma and/or Multicentric Castlemans's Disease\n* Has concurrent active hepatitis B (defined as hepatitis B surface antigen (HBsAg) positive and/or detectable HBV deoxyribonucleic acid (DNA)) and Hepatitis C virus (HCV) defined as anti-HCV antibody (Ab) positive and detectable HCV ribonucleic acid (RNA)) infection\n* Has had major surgery or significant traumatic injury within 4 weeks before the first dose of study intervention. Anticipation of the need for major surgery during the course of treatment with study intervention is also exclusionary\n* Has severe hypersensitivity (Grades \\>=3) to sacituzumab tirumotecan (MK-2870), any of its excipients, and/or to another biologic therapy\n* Has a history of (noninfectious) pneumonitis/ interstitial lung disease (ILD) that required steroids or has current pneumonitis/ILD", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"centralContacts": [{"name": "Toll Free Number", "role": "CONTACT", "phone": "1-888-577-8839", "email": "Trialsites@msd.com"}], "overallOfficials": [{"name": "Medical Director", "affiliation": "Merck Sharp & Dohme LLC", "role": "STUDY_DIRECTOR"}]}, "referencesModule": {"seeAlsoLinks": [{"label": "Merck Clinical Trials Information", "url": "https://www.merckclinicaltrials.com/"}, {"label": "Plain Language Summary", "url": "https://msd.trialsummaries.com/Study/StudyDetails?id=26288&tenant=MT_MSD_9011"}]}}, "hasResults": false}